

## NexoBrid®



### Disruptive Therapy for Burn Care FDA and EMA approved

- Approved in 40+ countries
- 16,000+ patients treated to date
- Poised to replace standard of care for eschar removal in severe burns
- Minimizes need for surgery and significantly reduces blood loss
- Topical application at bedside
- Preserves viable tissue and improves patient outcomes (scar quality and function)
- c-GMP sterile manufacturing facility to support global demand

## EscharEx®



### Bioactive Enzymatic Debridement Drug Candidate for Chronic Wounds

- Rapid, effective debridement and facilitation of wound closure
- Easy to use topical application for all patient settings
- Debrides chronic ulcers within 4-8 applications
- Promotes granulation tissue and reduces bacteria & biofilm
- Demonstrated superiority over SANTYL®
- Targets a \$2.5B+ market
- De-risked program; based on 3 successful Phase II trials
  - Ongoing Phase III trial for venous leg ulcers (VLU)
  - Trial for diabetic foot ulcers (DFU) planned H2 2026
  - Pressure ulcers (PU) Investigator-Initiated Trial (IIT) planned H2 2026
- Research collaborations with Mölnlycke, Solventum, Medline, Essity, B. Braun, Coloplast, Convatec and MIMEDX

## Global Collaborations



## Validated Enzymatic Technology Platform

### Solid Balance Sheet

**\$45M** cash (as of March 31 2026)

**\$17M** revenues in 2025

**\$120M** BARDA funding

**\$18M** DoW funding